Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
It is a single-center,exploratory clinical trial aimed to evaluate the objective response
rate (ORR) of Camrelizumab combined with apatinib and Temozolomide as First Line Therapy in
Advanced Acral Melanoma.